Press Releases

Keyword Search
 
2017 | 2016 | 2015 | 2014 | 2013
DateTitle  
12/29/15Vitae Pharmaceuticals Doses First Patients in Phase 2a Proof-of-Concept Trial of VTP-38543 in Atopic Dermatitis
Top-Line Results Expected in the Second Half of 2016 FORT WASHINGTON, Pa., Dec. 29, 2015 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE), a clinical-stage biotechnology company, today announced that it has dosed the first patients in its Phase 2a proof-of-concept clinical trial of VTP-38543 in atopic dermatitis (AD). VTP-38543 is the Company’s topical LXRβ selective agonist for the treatment of AD, a skin condition characterized by an intense itch / scratch cycle and driven by b... 
Download PDFPrinter Friendly Version
12/17/15Vitae Pharmaceuticals Reports Top-Line Results From Remaining Monotherapy Arm of Phase 2 Clinical Trial of BI187004 in Overweight Type 2 Diabetes Patients
FORT WASHINGTON, Pa., Dec. 17, 2015 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE), a clinical-stage biotechnology company, today announced top-line clinical efficacy results from the remaining monotherapy arm of Boehringer Ingelheim’s Phase 2 proof-of-concept trial of BI187004 (VTP-34072) in type 2 diabetes. This randomized, double-blind, placebo-controlled Phase 2 proof-of-concept trial assessed the safety, tolerability, efficacy, pharmacokinetics and pharmacodynamics of BI... 
Download PDFPrinter Friendly Version
12/14/15Vitae Pharmaceuticals Announces Addition to the NASDAQ Biotechnology Index
FORT WASHINGTON, Pa., Dec. 14, 2015 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE), a clinical-stage biotechnology company, today announced that it has been added to the NASDAQ Biotechnology Index (NASDAQ:NBI). The addition will become effective prior to the market open on Monday, December 21, 2015. Vitae is also included in the Russell 3000® and 2000® indices. The NASDAQ Biotechnology Index is designed to track the performance of a set of NASDAQ-listed securities that are cl... 
Download PDFPrinter Friendly Version
12/10/15Vitae Pharmaceuticals Opens Phase 2a Proof-of-Concept Trial of VTP-38543 in Atopic Dermatitis Patients
FORT WASHINGTON, Pa., Dec. 10, 2015 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE), a clinical-stage biotechnology company, today announced updated plans to begin clinical development of VTP-38543 with a four-week Phase 2a proof-of-concept trial that has been opened for patients with atopic dermatitis (AD). Previously, the Company had expected to initiate a Phase 1 clinical trial. The Company has started activities to initiate the Phase 2a trial and expects to begin dosing patient... 
Download PDFPrinter Friendly Version
11/24/15Vitae Pharmaceuticals to Present at 27th Annual Piper Jaffray Healthcare Conference
FORT WASHINGTON, Pa., Nov. 24, 2015 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE), a clinical-stage biotechnology company, today announced that Jeffrey Hatfield, President and Chief Executive Officer, will present a company overview at the 27th Annual Piper Jaffray Healthcare Conference on Tuesday, December 1, 2015 at 9:00 a.m. EST at The Lotte New York Palace Hotel. A live audio webcast of the presentation will be available via the "Investor Relations" page of the Vitae webs... 
Download PDFPrinter Friendly Version
11/18/15Vitae Pharmaceuticals Announces Positive Top-Line Results From a Phase 1 Multiple Ascending Dose Trial of VTP-43742
Multiple ascending doses of VTP-43742 shown to be safe and generally well tolerated in healthy human volunteers Robust ex vivo biomarker response, suppressing secretion of pro-inflammatory IL-17A by more than 90 percent Top-line proof-of-concept clinical results from Phase 1 trial of VTP-43742 in psoriatic patients expected in the first quarter of 2016 FORT WASHINGTON, Pa., Nov. 18, 2015 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE), a clinical-sta... 
Download PDFPrinter Friendly Version
11/12/15REMINDER: Vitae Pharmaceuticals to Host Analyst and Investor Briefing
Scheduled for 7:00 a.m. EST on November 19, 2015 Presentations to begin at 7:15 a.m. EST FORT WASHINGTON, Pa., Nov. 12, 2015 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE), a clinical-stage biotechnology company, will host an Analyst and Investor Briefing on Thursday, November 19, 2015 from 7:00 to 9:00 a.m. EST in New York, NY. Presentations will begin at 7:15 a.m. EST and leading academic experts are scheduled to speak. For additional information and registration... 
Download PDFPrinter Friendly Version
11/10/15Vitae Pharmaceuticals to Present at Stifel 2015 Healthcare Conference
FORT WASHINGTON, Pa., Nov. 10, 2015 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE), a clinical-stage biotechnology company, today announced that Jeffrey Hatfield, President and Chief Executive Officer, will present a company overview at the Stifel 2015 Healthcare Conference on Tuesday, November 17, 2015 at 11:00 a.m. EST at The New York Palace Hotel. A live audio webcast of the presentation will be available via the "Investor Relations" page of the Vitae website, www.vitaephar... 
Download PDFPrinter Friendly Version
11/05/15Vitae Pharmaceuticals Reports Third Quarter 2015 Operating and Financial Results
Announces psoriasis as lead indication for VTP-43742 Conference call scheduled for 4:30 p.m. EST today FORT WASHINGTON, Pa., Nov. 5, 2015 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE), a clinical-stage biotechnology company developing a robust and growing portfolio generated by its proprietary structure-based drug discovery platform, today reported its operating and financial results for the third quarter ended September 30, 2015. Jeff Hatfield, President and Chief Ex... 
Download PDFPrinter Friendly Version
11/02/15Vitae Pharmaceuticals to Announce Third Quarter 2015 Financial Results on November 5, 2015
FORT WASHINGTON, Pa., Nov. 2, 2015 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE), a clinical-stage biotechnology company, will host a conference call on Thursday, November 5, 2015 at 4:30 p.m. EST to discuss third quarter 2015 financial results and recent operational highlights. A question-and-answer session will follow Vitae's remarks. To participate on the live call, please dial 844-423-9893 (domestic) or +1-716-247-5808 (international) and provide the conference ID 7014119... 
Download PDFPrinter Friendly Version
10/20/15Vitae Pharmaceuticals to Host Analyst and Investor Briefing
Scheduled for 7:00 a.m. EST on November 19, 2015 FORT WASHINGTON, Pa., Oct. 20, 2015 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc. (Nasdaq:VTAE), a clinical-stage biotechnology company, will host an Analyst and Investor Briefing on Thursday, November 19, 2015 from 7:00 to 9:00 a.m. EST in New York, NY. For additional information and registration, please email vitae@westwicke.com or call 443-213-0506. A live audio webcast of the event will be available via the "Investor Relations" page... 
Download PDFPrinter Friendly Version
09/30/15Vitae Pharmaceuticals Appoints Dr. Karen Bernstein to Board of Directors
Charles W. Newhall, III Steps Down From Board FORT WASHINGTON, Pa., Sept. 30, 2015 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE), a clinical-stage biotechnology company, today announced the appointment of Karen Bernstein, Ph.D., to its board of directors, effective immediately. Dr. Bernstein is best known for co-founding and shaping BioCentury Publications Inc. into one of the biotechnology sector's most highly regarded sources of global industry intelligence. Dr. Bernstein step... 
Download PDFPrinter Friendly Version
09/29/15Vitae Pharmaceuticals Initiates Second Part of a Phase 1 Multiple Ascending Dose Study of VTP-43742 in Psoriatic Patients
Top-Line Proof-of-Concept Data in Psoriasis Patients Expected by the End of 2015 FORT WASHINGTON, Pa., Sept. 29, 2015 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE), a clinical-stage biotechnology company, today announced that it has initiated the second part of its Phase 1 multiple ascending dose clinical trial of VTP-43742 in psoriatic patients. VTP-43742 is the Company's wholly owned and first-in-class RORγt inhibitor product candidate for the treatment of autoimmune disorders... 
Download PDFPrinter Friendly Version
09/22/15Vitae Pharmaceuticals to Ring the NASDAQ Stock Market Closing Bell
FORT WASHINGTON, Pa., Sept. 22, 2015 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE), a clinical-stage biotechnology company, today announced that Jeff Hatfield, President and Chief Executive Officer, will ring the NASDAQ Closing Bell at the NASDAQ MarketSite in Times Square today at 4:00 p.m. ET. Mr. Hatfield will be joined by Vitae's executive leadership team to recognize the one-year anniversary of the Company's initial public offering (IPO). "I'm honored to ring the clo... 
Download PDFPrinter Friendly Version
09/08/15Vitae Pharmaceuticals Announces Positive Top-Line Results From Initial Phase 1 Study of First-in-Class RORyt Inhibitor VTP-43742 in Autoimmune Disorders
Single ascending doses of VTP-43742 safe and generally well-tolerated, demonstrated once-daily pharmacokinetics Robust ex vivo biomarker response, suppressing pro-inflammatory IL-17A by more than 90 percent FORT WASHINGTON, Pa., Sept. 8, 2015 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE), a clinical-stage biotechnology company, today announced positive top-line results from its Phase 1 single ascending dose clinical study of VTP-43742 in autoimmune disorders. VTP-4374... 
Download PDFPrinter Friendly Version
08/10/15Vitae Pharmaceuticals Announces Initiation of a Phase 1 Multiple Ascending Dose Study of VTP-43742 in Autoimmune Disorders
FORT WASHINGTON, Pa., Aug. 10, 2015 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE), a clinical-stage biotechnology company, today announced that it has initiated a Phase 1 multiple ascending dose clinical trial of VTP-43742, its wholly owned and first-in-class RORγt inhibitor product candidate for the treatment of autoimmune disorders, including psoriasis, psoriatic arthritis, ankylosing spondylitis, rheumatoid arthritis and multiple sclerosis, as well as numerous orphan indicatio... 
Download PDFPrinter Friendly Version
08/05/15Vitae Pharmaceuticals to Present at Wedbush PacGrow Healthcare Conference
FORT WASHINGTON, Pa., Aug. 5, 2015 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE), a clinical-stage biotechnology company, today announced that Jeffrey Hatfield, President and Chief Executive Officer, will present a company overview at the 2015 Wedbush PacGrow Healthcare Conference on Wednesday, August 12, 2015 at 9:10 a.m. EDT at the Le Parker Meridien New York. A live audio webcast of the presentation will be available via the "Investor Relations" page of the Vitae website, ... 
Download PDFPrinter Friendly Version
08/04/15Vitae Pharmaceuticals Reports Second Quarter 2015 Operating and Financial Results
Multiple potential milestones in 2H 2015 Conference call scheduled for 4:30 p.m. EDT today FORT WASHINGTON, Pa., Aug. 4, 2015 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE), a clinical-stage biotechnology company developing a robust and growing portfolio generated by its proprietary structure-based drug discovery platform, reported today its operating and financial results for the second quarter ended June 30, 2015. "During the second quarter of 2015, we initiated a Ph... 
Download PDFPrinter Friendly Version
07/29/15Vitae Pharmaceuticals Appoints Dr. John M. Leonard to Board of Directors
FORT WASHINGTON, Pa., July 29, 2015 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE), a clinical-stage biotechnology company, today announced the appointment of John M. Leonard, M.D., to its board of directors, effective immediately. A 30-year biopharmaceutical industry veteran, Dr. Leonard served as Chief Scientific Officer and Senior Vice President of Research & Development at AbbVie, Inc. following its spin-out from Abbott Laboratories in 2013 until his retirement. While at AbbVi... 
Download PDFPrinter Friendly Version
07/28/15Vitae Pharmaceuticals to Announce Second Quarter 2015 Financial Results on August 4, 2015
FORT WASHINGTON, Pa., July 28, 2015 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE), a clinical-stage biotechnology company, will host a conference call on Tuesday, August 4, 2015 at 4:30 p.m. EDT to discuss second quarter 2015 financial results and recent operational highlights. A question-and-answer session will follow Vitae's remarks. To participate on the live call, please dial 844-423-9893 (domestic) or +1-716-247-5808 (international) and provide the conference ID 94533069... 
Download PDFPrinter Friendly Version
07/27/15Vitae Pharmaceuticals and Boehringer Ingelheim to End Collaboration and License Agreement for BACE Inhibitors
Vitae Expects to Receive Rights to BI-1147560 / VTP-36951 Company to Assess Program to Determine Next Steps FORT WASHINGTON, Pa., July 27, 2015 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE), a clinical-stage biotechnology company, today announced that Boehringer Ingelheim (BI) has notified Vitae that BI is ending the parties' collaboration and license agreement for orally-active beta secretase (BACE) inhibitors for the treatment and prevention of Alzheimer's disease and o... 
Download PDFPrinter Friendly Version
06/29/15Vitae Pharmaceuticals Announces Top-Line Results From Metformin Arm of Ongoing Phase 2 Clinical Trial of BI187004/VTP-34072 in Overweight Type 2 Diabetics
FORT WASHINGTON, Pa., June 29, 2015 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE), a clinical-stage biotechnology company, today announced top-line clinical efficacy results from the metformin arm of an ongoing Phase 2 proof-of-concept clinical trial of BI187004/VTP-34072 in the treatment of overweight type 2 diabetic patients. BI187004/VTP-34072 is a potential first-in-class 11β-hydroxysteroid dehydrogenase type 1 (11β HSD1) inhibitor that was discovered by Vitae and is currentl... 
Download PDFPrinter Friendly Version
06/29/15Vitae Pharmaceuticals Announces Initiation of a Phase 1 Single Ascending Dose Study of VTP-43742 in Autoimmune Disorders
FORT WASHINGTON, Pa., June 29, 2015 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE), a clinical-stage biotechnology company, today announced the initiation of a Phase 1 single ascending dose clinical trial of VTP-43742, the Company's wholly owned and potential first-in-class RORγt inhibitor for the treatment of autoimmune disorders, including psoriasis, multiple sclerosis, and various arthropathies, as well as rare and orphan disorders. This single ascending dose trial will ass... 
Download PDFPrinter Friendly Version
06/16/15Vitae Pharmaceuticals to Present at JMP Securities Life Sciences Conference
FORT WASHINGTON, Pa., June 16, 2015 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc. (Nasdaq:VTAE), a clinical-stage biotechnology company developing a robust and growing portfolio generated by its proprietary structure-based drug discovery platform, today announced that Richard Morris, Chief Financial Officer, will present a company overview at the JMP Securities Life Sciences Conference on Tuesday, June 23, 2015 at 2:00 p.m. EDT at The St. Regis New York. A live audio webcast of the present... 
Download PDFPrinter Friendly Version
05/13/15Vitae Pharmaceuticals to Present at UBS Global Healthcare Conference
FORT WASHINGTON, Pa., May 13, 2015 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc. (Nasdaq:VTAE), a clinical-stage biotechnology company developing a robust and growing portfolio generated by its proprietary structure-based drug discovery platform, today announced that Jeffrey Hatfield, President and Chief Executive Officer, will present a company overview at the UBS Global Healthcare Conference on Wednesday, May 20, 2015 at 12:30 p.m. EDT at the Sheraton New York Times Square Hotel. A live ... 
Download PDFPrinter Friendly Version
05/12/15Vitae Pharmaceuticals Reports First Quarter 2015 Operating and Financial Results
Multiple impending 2Q inflection points supported by enhanced cash position Conference call scheduled for 4:30 p.m. EDT today FORT WASHINGTON, Pa., May 12, 2015 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc. (Nasdaq:VTAE), a clinical-stage biotechnology company developing a robust and growing portfolio generated by its proprietary structure-based drug discovery platform, reported today its operating and financial results for the first quarter ended March 31, 2015. "During the first ... 
Download PDFPrinter Friendly Version
05/06/15Vitae Pharmaceuticals to Present at Upcoming Meetings
FORT WASHINGTON, Pa., May 6, 2015 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc. (Nasdaq:VTAE), a clinical-stage biotechnology company developing a robust and growing portfolio generated by its proprietary structure-based drug discovery platform, announced that it will be presenting new data on several of its product candidates for the treatment of autoimmune diseases, atopic dermatitis and acute coronary syndrome at upcoming scientific meetings. IMMUNOLOGY 2015: The American Association of... 
Download PDFPrinter Friendly Version
05/05/15Vitae Pharmaceuticals to Announce First Quarter 2015 Financial Results on May 12, 2015
FORT WASHINGTON, Pa., May 5, 2015 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc. (Nasdaq:VTAE), a clinical-stage biotechnology company, will host a conference call on Tuesday, May 12, 2015 at 4:30 p.m. EDT to discuss first quarter 2015 financial results and recent operational highlights. A question-and-answer session will follow Vitae's remarks. To participate on the live call, please dial 844-423-9893 (domestic) or +1-716-247-5808 (international) and provide the conference ID 40302906 five... 
Download PDFPrinter Friendly Version
04/16/15Vitae Pharmaceuticals to Present at Keystone Symposia on Mechanisms of Pro-Inflammatory Diseases
FORT WASHINGTON, Pa., April 16, 2015 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc. (Nasdaq:VTAE), a clinical-stage biotechnology company, today announced that Gerard M. McGeehan, Ph.D., Vice President, Discovery Biology, will deliver an oral presentation related to VTP-43742, Vitae's RORγt product candidate for the treatment of autoimmune diseases, at the Keystone Symposia on Mechanisms of Pro-Inflammatory Diseases, which is being held April 19-24 at the Resort at Squaw Creek in Olympic Valley... 
Download PDFPrinter Friendly Version
03/31/15Vitae Pharmaceuticals Reports Fourth Quarter and Full Year 2014 Operating and Financial Results
Conference Call Scheduled for 8:30 a.m. EDT Today FORT WASHINGTON, Pa., March 31, 2015 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc. (Nasdaq:VTAE), a clinical-stage biotechnology company, reported today its operating and financial results for the fourth quarter and full year ended December 31, 2014. "We continue to make significant progress in advancing our RORγt program with our lead proprietary candidate, VTP-43742 for the treatment of autoimmune disorders, towards initiation of a Phase... 
Download PDFPrinter Friendly Version
03/27/15Vitae Pharmaceuticals to Announce Fourth Quarter and Full Year 2014 Financial Results on March 31, 2015
FORT WASHINGTON, Pa., March 27, 2015 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc. (Nasdaq:VTAE), a clinical-stage biotechnology company, will host a conference call on Tuesday, March 31, 2015 at 8:30 a.m. EDT to discuss fourth quarter and full year 2014 financial results and recent operational highlights. A question-and-answer session will follow Vitae's remarks. To participate on the live call, please dial 844-423-9893 (domestic) or +1-716-247-5808 (international) and provide the confere... 
Download PDFPrinter Friendly Version
02/27/15Vitae Pharmaceuticals to Present at Cowen and Company 35th Annual Health Care Conference
FORT WASHINGTON, Pa., Feb. 27, 2015 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc. (Nasdaq:VTAE), a clinical-stage biotechnology company, today announced that Jeffrey Hatfield, President and Chief Executive Officer, will present a company overview at the Cowen and Company 35th Annual Health Care Conference on Tuesday, March 3, 2015 at 8:00 a.m. EST at the Boston Marriott Copley Place. A live audio webcast of the presentation will be available via the "Investor Relations" page of the Vitae w... 
Download PDFPrinter Friendly Version
02/26/15BACE Inhibitor BI 1181181 Voluntarily Put on Temporary Clinical Hold for Safety Evaluation
FORT WASHINGTON, Pa., Feb. 26, 2015 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc. (Nasdaq:VTAE), a clinical-stage biotechnology company, today announced that its partner Boehringer Ingelheim has voluntarily placed BI 1181181 on a temporary clinical hold, and has notified regulatory agencies of its decision. BI 1181181 is an orally-active beta secretase (BACE) inhibitor being evaluated in Phase 1 clinical trials for the treatment and prevention of Alzheimer's disease. This action was taken to f... 
Download PDFPrinter Friendly Version
01/28/15Vitae Pharmaceuticals Announces Exercise of Underwriters' Option to Purchase Additional Shares and Closing of Follow-on Public Offering of Common Stock
FORT WASHINGTON, Pa., Jan. 28, 2015 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc. (Nasdaq:VTAE), a clinical stage biotechnology company, today announced the closing of its previously announced underwritten public offering. A total of 3,450,000 shares of its common stock were sold in the offering at a price to the public of $11.90 per share. The shares include 450,000 shares of common stock sold pursuant to the underwriters' option to purchase additional shares, which was exercised in full. Net... 
Download PDFPrinter Friendly Version
01/23/15Vitae Pharmaceuticals Announces Pricing of Follow-on Public Offering of Common Stock
FORT WASHINGTON, Pa., Jan. 23, 2015 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc. (Nasdaq:VTAE), a clinical stage biotechnology company, today announced the pricing of its follow-on public offering of 3,000,000 shares of its common stock at $11.90 per share. All shares of common stock to be sold in the offering are being offered by Vitae. Vitae has also granted the underwriters a 30-day option to purchase up to an additional 450,000 shares of common stock. The offering is expected to close... 
Download PDFPrinter Friendly Version
01/20/15Vitae Pharmaceuticals Launches Proposed Follow-on Public Offering of Common Stock
FORT WASHINGTON, Pa., Jan. 20, 2015 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc. (Nasdaq:VTAE), a clinical stage biotechnology company, today announced that it has commenced a proposed follow-on public offering of 3,000,000 shares of its common stock. All shares of common stock to be sold in the offering will be offered by Vitae. Vitae also expects to grant the underwriters a 30-day option to purchase up to an additional 450,000 shares of common stock in the public offering. Stifel, BMO C... 
Download PDFPrinter Friendly Version